Stock comparison
Corcept Therapeutics
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.41B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.13B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 79B | HALO |
| Benjamin Graham | 86C | 83A | CORT |
| Philip Fisher | 64C | 65B | HALO |
| Peter Lynch | 32F | 53D | HALO |
| Joel Greenblatt | 47D | 40D | CORT |
| Charlie Munger | 60C | 80C | HALO |
| Terry Smith | 68C | 84A | HALO |
Side-by-side metrics
| Metric | CORT | HALO |
|---|---|---|
| Market cap | $6.41B | $8.13B |
| P/E (TTM) | 122.0x | 24.0x |
| EV/EBIT | 131.9x | 10.2x |
| ROIC (TTM) | -1.23% | 23.65% |
| Gross margin | 98.25% | 81.24% |
| Net margin | 6.23% | 23.13% |
| Revenue CAGR 5y | 20.1% | 33.23% |
| EPS CAGR 5y | -0.52% | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 1.0x+98%
- EPS CAGR 5y-0.52%vs -1.98%+74%
- Gross margin98.25%vs 81.24%+17%
HALO leads on
- ROIC (TTM)23.65%vs -1.23%+105%
- EV/EBIT10.2xvs 131.9x+92%
- P/E (TTM)24.0xvs 122.0x+80%
- Net margin23.13%vs 6.23%+73%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.